Gynalven

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gynalven

Property Description
Active ingredient Progesterone (P4)
Form Soft capsule (often oil-based)
Pharmacological class Progestogen (Female Sex Hormone)
General purpose Hormone Signaling Restoration
Origin Bioidentical (Chemically identical to the endogenous human hormone)

What Type of Medicine Is Gynalven and What Does It Contain?

Gynalven is a prescription-only medicinal preparation classified as a progestogen, which represents a class of female sex hormones crucial for regulating the reproductive system. The drug is a single-active-ingredient product and contains Progesterone (P4) as its sole active component. This formulation is distinguished by providing micronized progesterone in a soft capsule form, often utilizing an oil-based vehicle, a method recognized for supporting systemic bioavailability.

The product's classification is significant because progesterone acts primarily as a powerful agonist of the progesterone receptor (PR), setting it apart from other major sex hormones, such as estrogen, and defining its specific role in hormone therapy.

Is the Progesterone in Gynalven Natural or Synthetic?

The progesterone in Gynalven is bioidentical; its chemical structure is an exact match for the endogenous progesterone produced naturally by the human ovary. This bioidentical status is a differentiating factor from chemically modified synthetic progestins. The active ingredient is provided as micronized progesterone, where the compound particles are reduced in size to enhance its absorption, which is a necessary step for effective delivery and action within the body.

What Is the General Purpose of Taking Gynalven?

The primary purpose of Gynalven is hormone signaling restoration, serving to supplement or replace insufficient levels of progesterone. This action is essential for establishing and maintaining hormonal equilibrium in various gynecological contexts, particularly in women.

By exerting its physiological action on the uterus, the medicine helps to stabilize the endometrium, changing the lining from a proliferative state to a secretory phase. This supports the environment necessary for specific reproductive processes, making Gynalven generally beneficial in fields such as assisted reproductive technology (ART) protocols and in specific regimens of hormone replacement therapy (HRT) where reliable progesterone supplementation is paramount.

What side effects are possible with Gynalven?

Possible Side Effects and Safety Information

The safety profile for Gynalven (micronized progesterone) is officially categorized by government health authorities, separating adverse reactions based on their frequency and the body system affected. These classifications dictate the formal understanding of the medicine's risks.

Adverse reactions that are frequently documented (Common or Very Common) often involve the Nervous System and Gastrointestinal System. Effects commonly listed include headache, somnolence (drowsiness), dizziness, and abdominal pain or nausea. The regulatory documents note that neurocognitive effects such as dizziness and drowsiness may be dose-dependent and can appear more frequently at the initiation of treatment.

Less frequently documented effects (Uncommon or Rare) can affect the Skin, resulting in reactions such as pruritus (itching) or urticaria (hives), and the Hepatobiliary System, with rare reports of jaundice.

Serious Adverse Reactions and Safety Constraints

The official labeling highlights specific serious risks associated with systemic progesterone use, particularly when part of Hormone Replacement Therapy. These risks include thromboembolic events, such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and stroke.

Regulatory agencies define specific Safety Constraints for this medicine. Gynalven is contraindicated in individuals with severe hepatic impairment or active liver disease, due to how the drug is metabolized by the liver. Furthermore, specific attention is advised for older adults regarding risks associated with vascular events and certain cancers when used in combination with estrogen.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile for the active ingredient in Gynalven (progesterone) by describing expected clinical presentations and establishing clear requirements for seeking emergency assistance. This information is derived strictly from government-authorized prescribing guidelines.

Documented Overdose Manifestations

According to regulatory labeling, an overdose may present with a specific cluster of clinical signs. These documented manifestations include effects on the central nervous system, such as sleepiness, dizziness, tiredness, and depressive mood. Gastrointestinal symptoms like nausea and vomiting are also listed as potential outcomes, alongside dermatologic effects such as acne and increased hairiness. Consulting a doctor is recommended if several capsules are accidentally taken.

Regulatory-Mandated Emergency Actions

Immediate medical attention is required in the event of a suspected overdose. The official documents explicitly state that users must contact the Poison Control Helpline or seek urgent medical guidance. Contacting emergency services immediately is mandated if severe, life-threatening symptoms are observed. These critical overdose triggers include collapse, seizure, trouble breathing, or the inability to be awakened.

Supportive Measures

Management of overdose, as described in official prescribing information, requires the discontinuation of the product. The mandatory procedural step is the institution of appropriate symptomatic and supportive care, as no specific antidote is detailed in the reviewed regulatory documents for this agent.

Therapeutic Uses of Gynalven

What Gynalven Treats: Main Uses and Benefits

The therapeutic areas for micronized progesterone generally align with three key clinical contexts. Gynalven is commonly used for supportive care for early pregnancy in fertility protocols, applied in the context of Hormone Replacement Therapy (HRT), and used for managing symptoms related to the uterine lining, cyclical distress, and menstrual irregularities.

It is applied across conditions associated with luteal phase deficiency and may be part of symptomatic management during Assisted Reproductive Technology (ART) procedures. The medication provides support that helps ease the overall symptom burden by assisting with maintaining functional stability of the uterine lining. The medicine also addresses severe symptom clusters that may become intense or disruptive during the premenstrual phase, including cyclical mood changes, anxiety, and breast tenderness, which contributes to improved day-to-day comfort.

Quick Fact

Applied in Addressing Symptoms Related to Cyclical Mood Changes

Eligibility and Restrictions for Use

The drug Gynalven contains the active substance progesterone. Official eligibility and non-eligibility rules are determined by governmental regulatory bodies (such as the EMA, FDA, and NIH) to ensure safety and define the population for whom the medicine is considered safe for use. Restrictions on use are formally outlined in the prescribing information or Summary of Product Characteristics (SmPC).

Official Eligibility Constraints (Progesterone)

Contraindicated Populations Use Not Recommended
Known hypersensitivity to progesterone, soy, or peanut Certain medications that increase progesterone metabolism
Known, past, or suspected breast cancer Use in the pediatric population
Known or suspected hormone-dependent malignant tumors Breastfeeding (contraindicated in some regulatory documents)
Undiagnosed genital bleeding Use in pregnancy (status depends on specific indication)
Previous or current thromboembolic disorders (e.g., DVT, pulmonary embolism)
Acute liver disease or history of liver disease (if function tests are abnormal)
Active arterial thromboembolic disease (e.g., heart attack, stroke)

These constraints define the official structure of the eligibility profile, requiring the medicine to not be used in individuals with a history of serious cardiovascular, liver, or hormone-dependent conditions, or certain cancers, as these factors formally increase the risk profile according to official regulatory documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the official regulatory documentation regarding interactions between Gynalven and other medicines or products. All information is strictly based on the officially documented pharmacokinetic interaction profile.

The primary concern outlined in regulatory documents is the risk of reduced therapeutic effectiveness when Gynalven is co-administered with medicines that act as strong hepatic enzyme inducers. These inducers accelerate the metabolism of the active substance, which can lead to a decrease in its concentration within the body.

Documented Interacting Medicinal Products

Official regulatory labeling explicitly lists the following medicinal products and substance categories as interacting agents due to their enzyme-inducing properties:

  • Antiepileptic Drugs: Specific examples include barbiturates, phenytoin, and carbamazepine.
  • Anti-infective Agents: Including rifampicin, efavirenz, and nevirapine.
  • Herbal Products: Specifically, the co-administration of products containing St. John's wort (Hypericum perforatum) is noted.

Interaction-Related Restriction

Because co-administration with these enzyme-inducing agents may result in a clinically relevant decrease in therapeutic effect, the official regulatory information states that the concomitant use of strong hepatic enzyme inducers should be avoided.

Mechanism of Action

Gynalven (Troxerutin) is a bioflavonoid derivative that modulates microvascular endothelial function through several pathways. The compound exhibits selective accumulation within endothelial cells of the microvasculature. Mechanistically, Troxerutin acts as an inhibitor of specific enzymatic activities, including aldose reductase and protein kinase C (PKC), which are implicated in cell signaling cascades that regulate vascular integrity.

Intracellularly, the inhibition of aldose reductase reduces the generation of reactive oxygen species and downstream products of the polyol pathway, modulating oxidative stress and associated cellular damage. Furthermore, Troxerutin interferes with the activation of PKC, a key enzyme involved in signal transduction pathways that regulate endothelial permeability and leukocyte-endothelium adhesion. Downstream cascades include the stabilization of the endothelial barrier function and a reduction in the expression of adhesion molecules on the endothelial surface. The system-level physiological consequence of these modulations is a decrease in microvascular hyperpermeability and a normalization of capillary filtration dynamics.

Dosage and Administration Information

Official Administration and Dosing for Gynalven

Gynalven (micronized progesterone) is a prescription medicine delivered in a soft capsule form, and its administration follows specific guidelines. The approved and standard route of administration for this formulation is oral (by mouth).


Standard Adult Dosing Regimens

The medicine is used in cyclic patterns and is generally taken once daily at bedtime. Dosing varies based on the specific clinical context, following these instructions:

Context Standard Daily Dose Schedule Pattern
Endometrial Protection (HRT) 200 mg For 12 continuous days per 28-day cycle.
Secondary Amenorrhea 400 mg For 10 consecutive days per cycle.

Procedural Instructions and Use Conditions

To ensure proper administration, the soft capsule must always be swallowed whole with a glass of water, and it must not be chewed or crushed. The general recommendation is to take the dose in the evening at bedtime.

Instructions regarding food intake may vary, though doses are often recommended at bedtime, with the 200 mg dose sometimes showing increased absorption when taken with food. The medication is not recommended for use in the pediatric population. If a dose is missed, patients are advised to skip the missed dose if it is almost time for the next scheduled dose, and not to double up on subsequent doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Activity Investigation

Studies examined the drug's activity and explored its potential association with pain modulation. Preclinical research has investigated the drug's interaction with specific receptor sites. Further research is ongoing to fully characterize the drug's investigated effect on neurotransmitter activity.


Clinical Study Findings

Clinical trials investigated the drug's effect on pain intensity. Most published studies were randomized, double-blind, placebo-controlled trials focusing on participants with moderate-to-severe non-malignant chronic pain.

Efficacy Parameter Evaluation

  • Monotherapy Trials: Studies examined the primary outcome of changes in pain intensity (measured using the VAS or NRS scales). Research investigated the drug's effect in participants with neuropathic pain. Initial trials explored dosage parameters ranging from 20 mg to 80 mg daily, with research documented a difference in reported pain scores when compared to placebo in certain participant groups.
  • Combination Investigation: Research investigated the combination's effect on pain intensity and compared findings to the drugs used as monotherapy. Research has also investigated the co-administration of the drug alongside physical therapy.

Long-term Data

Studies have explored whether long-term use may be related to changes in quality of life (assessed by the SF-36 questionnaire). Evidence remains limited regarding the effects on disease progression, but some open-label extension studies explored the drug's profile over periods up to 12 months. It is not yet clear from the available research whether the observed findings are maintained after treatment cessation.


Adverse Event Reporting

The drug's adverse event reporting has been evaluated across multiple studies. Adverse events reported in the research included drowsiness, dizziness, and mild gastrointestinal upset. Studies documented participant-reported onset of effect.

Due to the potential for side effects such as drowsiness, study protocols addressed the reporting of potential central nervous system effects.

Specific Populations

  • Elderly Participants: Research is limited for participants over the age of 75. Research involving older adults often included protocols for dosage investigation.
  • Participants with Liver/Kidney Impairment: Study protocols for participants with liver disease often included close monitoring of relevant clinical markers. Research findings are limited regarding dosage protocols for participants with severe kidney impairment.

Frequently Asked Questions (FAQ)

Common questions about Gynalven (FAQ)


Q: How quickly should I feel better after starting Gynalven?

Studies show that the active ingredient in Gynalven reaches its highest level in the bloodstream within a few hours of taking an oral dose. The time it takes for a patient to notice an improvement in symptoms, however, varies depending on the medical condition being addressed and is subject to individual variation. Patients are generally advised to continue their treatment as prescribed.


Q: Is Gynalven the same as other vaginal treatments I've used before?

The Gynalven formulation described in official product information is an oral soft capsule designed to be swallowed. This differs from many other gynecological treatments, which are administered vaginally. Official guidance emphasizes confirming the correct administration route for all prescription medications.


Q: What happens if I accidentally miss a day of using Gynalven?

According to the official administration instructions, if a dose is missed, patients are advised to skip that dose if it is almost time for your next scheduled dose. They should not take a double dose to make up for the missed one. The recommended approach is to continue with the regular schedule, skipping the missed dose.


Q: Is Gynalven safe to use if I'm trying to conceive?

The active ingredient in Gynalven, progesterone, is commonly utilized as part of assisted reproductive technology (ART) protocols for specific fertility challenges. However, its status for use during pregnancy is conditional and determined by the specific medical indication it is being used for, according to regulatory documents.


Q: What should I do if the Gynalven leaks out after application?

The Gynalven product described in official documents is an oral capsule that is swallowed. Leakage is a common experience, however, with vaginally administered progesterone products, which may be causing the user confusion about the route of administration. If a user has concerns about the product’s effectiveness or administration, consulting a professional source is recommended.


Q: Are there any dietary restrictions while using Gynalven?

Official information does not list specific dietary restrictions while taking Gynalven. The medication is often recommended to be taken in the evening at bedtime, with some documentation suggesting that taking it with food may increase absorption for certain doses.


Q: Can I use Gynalven if I'm taking supplements like probiotics?

The official documentation does not list general supplements like probiotics as interacting agents that affect Gynalven. The main concern outlined in regulatory documents is with strong hepatic (liver) enzyme-inducing agents, such as certain prescription medications and the herbal product St. John's wort.


Q: How is Gynalven different from over-the-counter vaginal remedies?

Gynalven is classified as a prescription-only medicine because it contains a hormone (progesterone) that is used to treat specific diagnosed conditions. Over-the-counter vaginal remedies, by contrast, are available without a prescription and usually contain non-hormonal ingredients for general symptom relief.


Q: Can Gynalven be stored in the bathroom or does it need to be refrigerated?

Official storage instructions require Gynalven to be kept at controlled room temperature (20^circ to 25 C) and protected from excessive moisture. Due to humidity fluctuations, storage in the bathroom is generally not recommended. The product should not be frozen or refrigerated.


Q: What's the difference between Gynalven and similar products with a different brand name?

Gynalven is a brand name for micronized progesterone, which is bioidentical (chemically identical) to the hormone naturally produced by the human body. Similar products may differ in their brand name, the specific inactive ingredients used, or the particular medical indications for which they are approved.


Q: Why do people sometimes say Gynalven is good for pelvic pain?

Gynalven's active ingredient, progesterone, is officially prescribed for specific gynecological conditions like secondary amenorrhea and is sometimes used to manage conditions like endometriosis. Since these conditions are common sources of pelvic discomfort, the medication may be associated with relief.


Q: Can I stop using Gynalven if my symptoms disappear early?

The medication is prescribed for a specific number of continuous days, such as 10 or 12 days per cycle, depending on the condition. To ensure the full therapeutic effect and complete the hormonal regimen, patients should use the medication for the entire duration prescribed.


Q: Does Gynalven help with dryness or just inflammation?

The official mechanism of action focuses on regulating hormone signaling and stabilizing the microvascular endothelium, which helps reduce swelling and capillary permeability. Relief of vaginal dryness is not listed as a primary mode of action in the regulatory documentation.


Q: Is Gynalven safe for people with chronic health conditions?

The official prescribing information lists specific contraindications, meaning the drug must not be used by individuals with a history of serious chronic conditions. These include acute liver disease, current or past thromboembolic disorders (like DVT or stroke), and certain hormone-dependent cancers.


Q: Can I use Gynalven during pregnancy?

The official regulatory guidance states that the status of Gynalven's use during pregnancy depends on the specific medical indication being treated. The final decision on use is reserved for a healthcare provider, consistent with the product’s official label.


Q: Is Gynalven meant to treat an infection or the symptoms of one?

Gynalven is classified as a progestogen, which is a female sex hormone used for hormone signaling restoration. It is not classified or indicated as an anti-infective agent for treating bacterial or fungal infections.


Q: How do I properly dispose of unused Gynalven?

Unused or expired medicine must be disposed of according to local requirements and should not be discarded into household waste or wastewater, as this can lead to environmental contamination. A pharmacist can provide guidance on local medicine collection or take-back programs.


Q: Is there a generic version of Gynalven available?

Gynalven is a brand name for micronized progesterone capsules. Generic versions of the active ingredient, micronized progesterone, are widely available on the market.


Q: How long does it take for the active ingredient in Gynalven to be absorbed?

Following oral administration, the active ingredient is quickly absorbed into the body. Official pharmacokinetic data shows that the highest concentration in the blood is typically reached within a few hours after taking the capsule.


Q: Can Gynalven be used during a menstrual period?

The official dosing is based on specific cyclic patterns, such as 10 or 12 consecutive days per 28-day cycle. This means the treatment is usually taken during certain phases of the menstrual cycle, rather than continuously throughout a menstrual period.


Q: Can Gynalven be used by women of all ages?

Regulatory documents state that the medication is not recommended for use in the pediatric population. Contraindications and special considerations also exist for older adults, particularly when the drug is used in combination with estrogen as part of hormone replacement therapy.


Q: Are there any long-term side effects associated with using Gynalven?

Studies have explored the drug’s profile for periods up to 12 months. Official labeling highlights specific serious risks associated with long-term systemic progesterone use, particularly as part of Hormone Replacement Therapy. These risks include thromboembolic events (DVT, PE, stroke) and certain cancer risks.


Q: What is the recommended duration of treatment with Gynalven?

The duration of treatment is clearly defined based on the condition being addressed. For example, it is typically taken for 12 continuous days per 28-day cycle for endometrial protection, or for 10 consecutive days per cycle for secondary amenorrhea.


Q: Are the side effects of Gynalven generally mild or severe?

Adverse reactions are officially classified into frequency categories. Frequently documented effects, such as headache and drowsiness, are generally considered mild. However, the official labeling also highlights the potential for specific serious, though less common, risks such as thromboembolic events (blood clots).


Q: Does Gynalven interact with common pain relievers like ibuprofen?

The main concern regarding drug interactions is with medicines that act as strong hepatic (liver) enzyme inducers. Common pain relievers like ibuprofen are generally not classified in regulatory documents as enzyme inducers, meaning they are not typically listed as official interacting agents.

How should Gynalven be stored and disposed of?

How to Store and Dispose of Gynalven?

The official storage and disposal requirements for Gynalven (micronized Progesterone soft capsules) must be strictly followed to ensure the medicine's stability and safety.


Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature (20^circ to 25 C or 68^circ to 77 F). Keep from freezing and do not store above 30 C.
Protection Keep the medicine in its original package to protect it from light and excessive moisture.
Safety Store the product out of the sight and reach of children.

Disposal Instructions

Any unused or expired Gynalven must be disposed of in accordance with local requirements. It is essential not to discard the medicine via household waste or wastewater to prevent environmental contamination; consult a pharmacist for guidance on local collection points.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gynalven found in:

A-Z Index: